Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 40/73 ]
NASDAQ | Common Stock
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers.
It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer.
The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer.
It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers.
The company was founded in 2009 and is headquartered in Westminster, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -0.96 Decreased by -141.81% | -0.17 Decreased by -481.82% |
| Aug 12, 25 | -0.27 Decreased by -28.57% | -0.22 Decreased by -22.73% |
| Apr 15, 25 | -0.40 Increased by +33.33% | -0.48 Increased by +16.67% |
| Mar 27, 25 | -0.40 Increased by +74.36% | -0.35 Decreased by -14.29% |
| Nov 14, 24 | -0.40 Decreased by -199.85% | -0.36 Decreased by -8.77% |
| Aug 15, 24 | -0.21 Decreased by -70.32% | -0.46 Increased by +54.35% |
| May 15, 24 | -0.60 Decreased by -998.90% | -0.65 Increased by +7.69% |
| Dec 31, 23 | -1.56 Decreased by -15.50 K% | -0.69 Decreased by -126.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 11.57 M Increased by +57.38% | -10.81 M Decreased by -350.65% | Decreased by -93.47% Decreased by -186.34% |
| Jun 30, 25 | 11.21 M Increased by +52.27% | -8.29 M Decreased by -91.32% | Decreased by -73.91% Decreased by -25.65% |
| Mar 31, 25 | 9.17 M Increased by +41.97% | -10.38 M Increased by +21.51% | Decreased by -113.18% Increased by +44.72% |
| Dec 31, 24 | 8.26 M Increased by +44.40% | -10.11 M Increased by +71.53% | Decreased by -122.36% Increased by +80.29% |
| Sep 30, 24 | 7.35 M Increased by +41.52% | -2.40 M Decreased by -68.35% | Decreased by -32.64% Decreased by -18.96% |
| Jun 30, 24 | 7.36 M Increased by +59.67% | -4.33 M Increased by +69.00% | Decreased by -58.83% Increased by +80.58% |
| Mar 31, 24 | 6.46 M Increased by +116.39% | -13.22 M Decreased by -59.88% | Decreased by -204.72% Increased by +26.11% |
| Dec 31, 23 | 5.72 M Increased by +77.34% | -35.51 M Decreased by -57.52% | Decreased by -620.68% Increased by +11.17% |